Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) makes the list of 12 hot penny stocks to invest in right now with a strong three-month performance and significant upside potential.

Barclays reduces Orchestra BioMed Holdings, Inc. (OBIO) price target from $12 to $11, maintaining an “Overweight” rating. The adjustment is based on the company’s clinical and strategic achievements outlined in its Q3 earnings report.

Orchestra BioMed Holdings, Inc. (OBIO) reports a net loss of $20.8 million, or $0.40 per share, for Q3 2025, up from $15.4 million loss in Q3 2024. R&D expenses increase to $14 million due to the ongoing BACKBEAT pivotal study.

Orchestra BioMed Holdings, Inc. (OBIO) raises $147.6 million through strategic transactions and equity offerings in Q3 2025, supporting trials for AVIM therapy and Virtue SAB. Strong momentum in Virtue SAB pivotal trial is expected to reach full enrollment in mid-2027.

Orchestra BioMed Holdings, Inc. (OBIO) focuses on advancing AVIM therapy and Virtue SAB in pivotal trials targeting hypertension and coronary artery disease.

Although OBIO shows investment potential, certain AI stocks offer greater upside potential with less downside risk. For undervalued AI stock with potential benefits from Trump-era tariffs and onshoring trend, see the best short-term AI stock.

Disclosure: None.

Read more at Yahoo Finance: Analyst Confidence in Orchestra BioMed Holdings (OBIO) High Amid Key Clinical and Strategic Advancements